Juliana, Living with Hpp

STRENSIQ improves
bone health

By addressing the underlying cause of hypophosphatasia (HPP), STRENSIQ® (asfotase alfa) improves bone health. Healthier bones can lead to improved mobility in people living with HPP.

Jump Btn

STUDIED IN ALL AGES

Bone health and mobilitya were studied in children and adults receiving treatment with STRENSIQ.


STRENSIQ was studied in children and adults, but only in those with signs and symptoms that appeared before 18 years of age.

Clinical studies chart

Select secondary endpoints are in bold in the table above.

Abbreviations: PLP, pyridoxal 5'-phosphate (vitamin B6); PPi, inorganic pyrophosphate.
aMobility is a person’s ability to walk.
bHPP is when your body lacks sufficient ALP enzyme and you develop weak or “soft” bones, which may lead to skeletal deformities, tooth loss or pain, or other related symptoms.
cPPi and PLP are substances found in blood that are related to ALP activity.
dGrowth refers to changes in body size based on age over time.

STRENSIQ IMPROVES SKELETAL HEALING

Study 1 and 2 primary endpoints

Improvements in HPP-related bone health/mineralization

Study 1 included patients up to three years of age with signs and symptoms that appeared before six months of age. At six months, 90% (9/10) of patients responded to treatment, which was sustained at seven years.

Study 2 included patients up to five years of age with signs and symptoms that appeared before six months of age. At six months, 58% (40/69) of patients responded to treatment, which was sustained at six years.

The primary endpoint is the outcome that establishes a medication’s effectiveness and safety when it goes through testing. The secondary endpoints demonstrate additional effects after success on the primary endpoint is shown.

Study 1

90%

AFTER 6 MONTHS OF STRENSIQ

treatment achieved complete or substantial bone healing

100%

AFTER 7 YEARS OF STRENSIQ

treatment achieved complete or substantial bone healing (7/7)

Study 2

58%

AFTER 6 MONTHS OF STRENSIQ

treatment achieved complete or substantial bone healing

100%

AFTER 6 YEARS OF STRENSIQ

treatment achieved complete or substantial bone healing (2/2)

SKELETAL HEALING

Study 3 primary endpoint

Improvements in HPP-related bone health/mineralization

Study 3 included patients from ages 6 years to 12 years that included perinatal/infantile- and juvenile-onset HPP patients.

At six months, 69% (9/13) of patients responded to treatment, which was sustained at seven years (12/12).

  • one child did not complete this study
69%
69%

AFTER 6 MONTHS OF STRENSIQ

treatment achieved complete or substantial bone healing

100%

AFTER 7 YEARS OF STRENSIQ

treatment achieved complete or substantial bone healing

STRENSIQ IMPROVES MOBILITY

Study 3 select secondary endpoints

Mobility

Six-Minute Walk Test (6MWT)a was conducted in 11 out of 13 children aged 6-12 years with HPP during the study. In the 11 children, the % of their predictedb walking distance reached the normal range after 6 months of treatment and improvements were sustained over seven years.
Watch the 6-minute
walk test for childrenc
Mobility and 6-minute walk test graph for children

a6MWT is the distance walked measured over a 6-minute time period.
bThis refers to the percentage of the distance a healthy person of similar age, sex, and height would be expected to walk in 6 minutes.
cRepresentations of efficacy are consistent with results seen from typical patients in the study. Individual results may vary.

During the 6-minute walk test, a person is asked to walk as far as they can for 6 minutes. This test is helpful when determining if someone has trouble with mobility.

CHANGE IN PLASMA PPi AND PLP

Study 4 design

  • Study 4 spanned five years and included adolescents and adults aged 13 to 65 years with signs and symptoms of HPP that appeared before 18 years of age (for 18 of the 19 study patients).
  • The primary endpoints of this study were to measure reductions of PPi and PLP, which are substances found in the blood that are related to ALP enzyme activity and bone health. If PPi and PLP are high, ALP activity is generally low.
  • Over the initial duration of the study, STRENSIQ was administered at lower doses than the FDA-approved dose (weight-based dose of 6 mg/kg per week).
  • The most frequently reported adverse events were injection-site reactions.
  • This data is not included in the FDA-approved Prescribing Information.
Study for primary endpoints

MOBILITY AS MEASURED BY THE 6-MINUTE WALK TEST (6MWT)

Study 4 select secondary endpoint

Mobility

Change in 6MWT was observed by 6 months and again at 5 years.
Watch the 6-minute
walk test for adults
Mobility and 6-minute walk test graph for adolescents and adults

*This refers to the percentage of the distance a healthy person of similar age, sex, and height would be expected to walk in 6 minutes.

STRENSIQ SIDE EFFECTS

Adverse reactions reported in at least 10% of patients with perinatal/infantile- or juvenile-onset HPP enrolled in STRENSIQ clinical trials

Side effects of Strensiq

aAdverse reactions are from the combined period of 6 mg/kg and above (ie, total drug exposure regardless of starting dose and intermediary doses as long as the patient reached doses >6 mg/kg)

HPP PATIENT SUPPORT

Enroll in OneSource™ to get personalized patient support from Alexion at 1.888.765.4747.

Learn More about OneSource™
One source Logo
Strensiq Logo

AT ONESOURCE, WE ARE BY YOUR SIDE THROUGHOUT YOUR JOURNEY, FROM LEARNING ABOUT YOUR CONDITION TO HELPING YOU ACCESS THE THERAPY YOU'VE BEEN PRESCRIBED. PATIENTS' NEEDS ARE OUR TOP PRIORITY.

–Deana,
ONESOURCE CASE MANAGER

One source Logo
Strensiq Logo

Ready to get started with strensiq?

Once your doctor prescribes STRENSIQ, Alexion and OneSource™ will be there to guide you on your STRENSIQ treatment journey. See the resources available as you start treatment with STRENSIQ.

Request a strensiq patient starter kit
- +
IMPORTANT SAFETY INFORMATION & INDICATION FOR STRENSIQ® (asfotase alfa)

STRENSIQ may cause serious side effects, including

  • Serious allergic (hypersensitivity) reactions happened in some people who use STRENSIQ. Stop using STRENSIQ and go to the nearest hospital emergency room right away if you or your loved one have any of the signs and symptoms of a serious allergic reaction, including
    • Difficulty breathing
    • Swelling of your eyes, lips, or tongue
    • Hives
    • Feeling faint
    • Nausea or vomiting
    • Dizziness
    • Itching of your lips, tongue, or throat
    • Choking sensation
  • Skin thickening or pits at the injection site (lipodystrophy) has happened several months after using STRENSIQ.
  • Calcium buildup in the eyes and kidneys can occur if you or your loved one have HPP. Your healthcare provider should check the eyes and kidneys while you or your loved one use STRENSIQ.
  • Decreased efficacy. Contact your healthcare provider if you or your loved one notice STRENSIQ is no longer working or experience worsening symptoms of HPP (e.g., increased respiratory support, increased difficulty walking, new fractures).

The most common side effects of STRENSIQ include local skin injection-site reactions (red skin patches, bruising, color change, pain, itching, thinning, swelling, pits, and bumps) and calcium buildup in your eyes and kidneys.

STRENSIQ may affect other lab test results, therefore it is important that you present your Medical Alert Card to your healthcare team so they are aware that you are being treated with an alkaline phosphatase (ALP) replacement therapy which may cause incorrect results on certain laboratory tests.

Tell your doctor if you are pregnant or plan to become pregnant or are breastfeeding or plan to breastfeed.

These are not all the possible side effects of STRENSIQ. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1‑800‑FDA‑1088.

INDICATION
What is STRENSIQ?
STRENSIQ is a prescription medicine used to treat people with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).

Please see STRENSIQ full Prescribing Information, including Patient Information and Instructions for Use.
IMPORTANT SAFETY INFORMATION & INDICATION FOR STRENSIQ® (asfotase alfa)

STRENSIQ may cause serious side effects, including

  • Serious allergic (hypersensitivity) reactions happened in some people who use STRENSIQ. Stop using STRENSIQ and go to the nearest hospital emergency room right away if you or your loved one have any of the signs and symptoms of a serious allergic reaction, including
    • Difficulty breathing
    • Swelling of your eyes, lips, or tongue
    • Hives
    • Feeling faint
    • Nausea or vomiting
    • Dizziness
    • Itching of your lips, tongue, or throat
    • Choking sensation
  • Skin thickening or pits at the injection site (lipodystrophy) has happened several months after using STRENSIQ.
  • Calcium buildup in the eyes and kidneys can occur if you or your loved one have HPP. Your healthcare provider should check the eyes and kidneys while you or your loved one use STRENSIQ.
  • Decreased efficacy. Contact your healthcare provider if you or your loved one notice STRENSIQ is no longer working or experience worsening symptoms of HPP (e.g., increased respiratory support, increased difficulty walking, new fractures).

The most common side effects of STRENSIQ include local skin injection-site reactions (red skin patches, bruising, color change, pain, itching, thinning, swelling, pits, and bumps) and calcium buildup in your eyes and kidneys.

STRENSIQ may affect other lab test results, therefore it is important that you present your Medical Alert Card to your healthcare team so they are aware that you are being treated with an alkaline phosphatase (ALP) replacement therapy which may cause incorrect results on certain laboratory tests.

Tell your doctor if you are pregnant or plan to become pregnant or are breastfeeding or plan to breastfeed.

These are not all the possible side effects of STRENSIQ. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1‑800‑FDA‑1088.

INDICATION
What is STRENSIQ?
STRENSIQ is a prescription medicine used to treat people with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).

Please see STRENSIQ full Prescribing Information, including Patient Information and Instructions for Use.